As a part of ClinOne and our CEO’s personal mission, ClinOne will start compensating/reimbursing caregivers of clinical trial participants for their very significant contribution to research, and the incredible amount of support they commit in supporting patients...
– Global clinical trial underway in 11 countries, including U.S., European, and Eastern European sites to evaluate safety, efficacy and tolerability of orally administered, gut-restricted LANCL2 agonist BT-11, in patients with mild to moderate ulcerative colitis –...
Study will evaluate the safety and preliminary efficacy of AR-13503 SR Implant as monotherapy and in combination with aflibercept — Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and...
Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, an ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD) and other retina...
Trial with once a day oral dosing to be conducted in 232 patients with moderate to severe ulcerative colitis at more than 150 sites in over 15 countries Published 9-month interim results of ongoing Phase 2a maintenance study ABX464-102 confirmed durability of safety...
ViewRay Incorporated, (Nasdaq: VRAY) announced today the acceptance of publication by the International Journal of Radiation Oncology, Biology and Physics of the first prospective clinical trial of MR-guided radiation therapy (MRgRT) in patients with localized...
Email
Text